June 15, 2025

The Silent Fracture: Understanding Osteoporosis

The player is loading ...
The Silent Fracture: Understanding Osteoporosis

Send us a text The silent, stealthy nature of osteoporosis makes it one of medicine's most challenging conditions. Patients can lose precious bone mass for years with absolutely no symptoms, only discovering their condition after a devastating, life-altering fracture. With over a million Australians affected and our population steadily aging, understanding how to identify, investigate and treat this condition couldn't be more crucial. Yet despite its prevalence, osteoporosis remains severely...

Send us a text

The silent, stealthy nature of osteoporosis makes it one of medicine's most challenging conditions. Patients can lose precious bone mass for years with absolutely no symptoms, only discovering their condition after a devastating, life-altering fracture.

With over a million Australians affected and our population steadily aging, understanding how to identify, investigate and treat this condition couldn't be more crucial. Yet despite its prevalence, osteoporosis remains severely underdiagnosed and undertreated in clinical practice.

In this comprehensive episode, Dr Gavin Nimon ( host and Orthopaedic Surgeon) inteviews Endocrinologist Dr Linn Lee brings about this complex topic. She expertly guides us through interpreting those notoriously confusing DEXA scan reports, breaking down T-scores and Z-scores into practical insights you can immediately apply. You'll discover exactly who needs investigating, when to refer to specialists, and how various risk assessment tools like FRAX and Garvan calculators can quantify fracture risk beyond bone density measurements alone.

Dr Lee demystifies the expansive pharmacological landscape – from bisphosphonates to cutting-edge anabolic agents – with particular attention to selecting the right medication for specific patient profiles. She discusses potential complications like osteonecrosis and atypical femoral fractures with refreshing honesty, providing evidence-based context about their prevalence and management strategies to mitigate risks.

Perhaps most valuable is the practical guidance on monitoring treatment efficacy, managing medication side effects, and navigating challenging clinical scenarios like bisphosphonate "drug holidays" and the complexities of stopping denosumab. The discussion extends beyond medications to emphasize the critical role of calcium, vitamin D, and targeted exercise regimens in comprehensive bone health management.

Whether you're a medical student building your foundational knowledge or an experienced GP managing complex cases, this episode delivers the practical insights you need to provide optimal care for patients with this prevalent but often overlooked condition. Subscribe to Aussie Med Ed for more expert-led, pragmatic discussions on core medical topics.

Aussie Med Ed is sponsored by -HealthShare is a digital health company, that provides solutions for patients, General Practitioners and Specialists across Australia.

 

Aussie Med Ed is sponsored by Avant  Medical Indemnity: They state that they offer holistic support to help the doctor practice safely and believe they have extensive cover that's continually evolving to meet your needs in the ever changing regulatory environment.

 

00:00 - Introduction to the Silent Disease

05:12 - Defining Osteoporosis and Risk Factors

11:29 - Diagnosing with DEXA and Fracture Risk

18:36 - Bone Turnover Markers and Specialist Referrals

21:58 - Lifestyle Modifications and Exercise

25:15 - Bisphosphonates and Anti-resorptive Treatments

34:11 - Anabolic Agents and Bone Building

40:25 - Drug Holidays and Side Effect Management

WEBVTT

00:00:00.140 --> 00:00:07.750
Osteoporosis is often called a silent disease because it can progress for years without symptoms, only to reveal itself through a sudden devastating fracture.

00:00:07.750 --> 00:00:12.832
It affects more than a million Australians and is a major cause of morbidity in our ageing population.

00:00:12.832 --> 00:00:15.929
Yet it's frequently underdiagnosed and undertreated.

00:00:15.929 --> 00:00:26.062
General practitioners and all doctors play a crucial role in identifying at-risk patients, initiating investigations and starting early treatment to prevent long-term complications.

00:00:26.062 --> 00:00:36.423
So how do we know who to screen, what medications truly make a difference and how do we know how to navigate the risks and benefits of treatment, especially in elderly or complex patients?

00:00:36.423 --> 00:00:45.491
Welcome back to Aussie Med Ed, a podcast where we take a pragmatic and relaxed dive into core medical topics designed especially for medical students and general practitioners.

00:00:45.491 --> 00:00:53.280
I'm your host, dr Gavin Lyman, and today we're unpacking the diagnosis and treatment of osteoporosis with Dr Lynne Lee G'day.

00:00:53.280 --> 00:01:14.094
And welcome to Aussie Med Ed, the Aussie-style medical podcast, our pragmatic and relaxed medical podcast designed for medical students and general practitioners, where we explore relevant and practical medical topics with expert specialists Hosted by myself, gavin Lyman, an orthopaedic surgeon, this podcast provides insightful discussions to a hunch of clinical knowledge without unnecessary jargon.

00:01:14.778 --> 00:01:20.186
I'd like to start the podcast by acknowledging the Kaurna people as the traditional custodians of the land on which this podcast is produced.

00:01:20.186 --> 00:01:25.246
I'd like to pay my respects to the elders, both past, present and emerging, and recognising their ongoing connection to land, waters and culture.

00:01:25.246 --> 00:01:26.998
I'd like to pay my respects to elders, both past, present and emerging, and recognising their ongoing connection to land, waters and culture.

00:01:26.998 --> 00:01:31.852
I'd like to say that this podcast is for educational purposes only and does not constitute medical advice.

00:01:31.852 --> 00:01:38.006
Always refer to clinical guidelines and consult a qualified healthcare professional before making medical decisions.

00:01:38.006 --> 00:01:42.191
In today's episode, we're discussing the diagnosis and treatment of osteoporosis with Dr Lynne.

00:01:42.230 --> 00:01:49.209
Lee Lynne is a specialist endocrinologist with a particular interest in bone health, reproductive endocrinology and diabetes management.

00:01:49.209 --> 00:01:59.870
After graduating from the University of Adelaide, she completed her advanced training in endocrinology at the Lyme Acute Hospital and Flinders Medical Centre and is a fellow of the Royal Australasian College of Physicians.

00:01:59.870 --> 00:02:04.387
She practices privately as South Australian medical specialist here in South Australia.

00:02:04.387 --> 00:02:12.668
Dr Lee is also undertaking dual training in chemical pathology, giving her a unique depth of insight into the biochemical basis of endocrine conditions.

00:02:12.668 --> 00:02:14.391
Welcome, dr Lee.

00:02:14.391 --> 00:02:18.151
Thank you very much for coming on board for Aussie Med Ed Lynn, and it's great to have you here with us.

00:02:18.151 --> 00:02:24.468
Perhaps you can tell me a little bit about what osteoporosis actually is and what the difference is between osteoporosis and osteopenia.

00:02:26.000 --> 00:02:27.062
Absolutely so.

00:02:27.062 --> 00:02:35.484
Osteoporosis is a condition defined by low bone mass and deterioration in the microarchitectural quality of the bone.

00:02:35.484 --> 00:02:47.473
It's incredibly common, a huge public health concern, and I guess the easiest way to define it is purely by the radiological kind of definition.

00:02:47.473 --> 00:02:54.731
So osteopenia is defined by a T-score between minus one and minus 2.5.

00:02:54.731 --> 00:03:05.210
So that's between one to two and a half standard deviations below what you'd expect for a 30-year-old of the same sex, and osteoporosis is defined as a T-score of lower than minus 2.5.

00:03:05.210 --> 00:03:14.022
So I guess you could say osteopenia is that sort of milder form, that sort of pre-osteoporosis stage before bone density really gets that low.

00:03:14.544 --> 00:03:16.588
So 30-year-olds use as a standard, is it?

00:03:16.830 --> 00:03:17.632
Essentially, yeah.

00:03:17.632 --> 00:03:22.883
So when you use a T-score, you're comparing it with 30-year-old bone density of the same sex.

00:03:23.204 --> 00:03:26.086
Yeah, Okay, how common actually is osteoporosis?

00:03:26.766 --> 00:03:27.487
It's very common.

00:03:27.487 --> 00:03:48.391
So it's been estimated that in all Australians over the age of 35 years it's about 2.7% of that population and that incidence rises markedly after the age of 75 in women, and it's generally postmenopausal women that have the highest incidence of osteoporosis, but pretty common even in the 35 to 90-year-old population.

00:03:48.391 --> 00:03:49.334
Yeah, Excellent.

00:03:49.721 --> 00:03:50.986
It's more common in women than men.

00:03:51.539 --> 00:03:52.103
Definitely.

00:03:52.103 --> 00:03:59.133
Yeah, it's probably a lot to do with the fact that women go through menopause so essentially hypogonadal.

00:03:59.133 --> 00:04:05.224
They lose that estrogen that provides a lot of suppression of bone turnover and they end up developing osteoporosis a lot easier.

00:04:05.224 --> 00:04:07.831
It's a lot less common in men, but certainly happens as well.

00:04:08.240 --> 00:04:12.412
So it's not based purely on the fact that men have a higher bone load initially.

00:04:12.412 --> 00:04:15.209
It's based purely on compared to the same sex.

00:04:15.600 --> 00:04:17.225
No, that's absolutely a good point.

00:04:17.225 --> 00:04:30.730
So we know that having a higher body mass generally causes more weight bearing on the bones and leads to achievement of a higher peak bone mass and therefore you tend to have a higher mass to start with.

00:04:30.730 --> 00:04:33.343
So you lose less and you're less likely to develop osteoporosis.

00:04:33.343 --> 00:04:41.336
But I think a big part of why women get it more is because of menopause, and we know that postmenopausal women are the biggest group.

00:04:41.336 --> 00:04:44.425
If you compare premenopausal women, that's a much smaller group.

00:04:45.127 --> 00:04:47.132
What are the other risk factors for osteoporosis?

00:04:52.199 --> 00:04:52.560
Yeah, absolutely so.

00:04:52.560 --> 00:04:53.002
Lots of risk factors.

00:04:53.002 --> 00:05:02.271
Probably the most common ones to consider when assessing a patient, for example, would be whether there's a family history of osteoporosis, particularly if there's been a family history of hip fracture in either parent.

00:05:02.271 --> 00:05:05.488
That's actually used in the FRAX calculation score.

00:05:05.488 --> 00:05:33.127
I always ask my patients about alcohol intake the less the better with regards to bone density, and we consider other things like calcium intake as well, whether that's been adequate, vitamin D deficiency and then significant comorbidities, such as any kind of malabsorption conditions like celiac disease, malnutrition, low bone density and low weight bearing states such as people that are confined to wheelchairs or bed bound.

00:05:33.127 --> 00:05:43.439
And there are other conditions like inflammatory sort of disorders, like rheumatoid arthritis, glucocorticoid use, of course, diabetes mellitus, chronic kidney disease.

00:05:43.439 --> 00:05:51.802
A lot of these chronic multi-organ illnesses tend to raise the risk of osteoporosis as well, but those are probably the main ones I tend to ask about.

00:05:52.444 --> 00:06:00.290
In my reading I was hearing that obviously smoking is a factor and then with smoking and reduced body mass, it's also a factor.

00:06:00.290 --> 00:06:12.124
Is the cause of smoking being a factor on causing osteoporosis the fact that people who smoke may have a lower body mass because of the appetite suppression or the malabsorption or was it actually a primary effect itself?

00:06:12.745 --> 00:06:25.505
yeah, I'm not aware that smoking is a primary risk factor and directly interferes with bone metabolism, but certainly those links that you described, I could absolutely see that happening.

00:06:25.505 --> 00:06:34.807
Lower bone density maybe might be associated with lower nutrition as well, and I do ask that as part of my routine history, but I don't focus on it so much as a risk factor.

00:06:35.129 --> 00:06:39.949
Yeah, and obviously there's also a lot of medications, too, that can interfere as well with it.

00:06:40.029 --> 00:06:40.630
So what are?

00:06:40.651 --> 00:06:41.923
the main ones you would tend to see.

00:06:42.223 --> 00:06:43.425
Yeah, absolutely so.

00:06:43.425 --> 00:06:45.089
I already mentioned glucocorticoids.

00:06:45.089 --> 00:06:51.985
That's a big one, and we have a much lower threshold to treat people with osteoporosis if we know they're on corticosteroids.

00:06:51.985 --> 00:06:59.005
The other ones I see are women who use certain progesterone-only contraceptions, such as the Depo-Provera.

00:06:59.005 --> 00:07:03.629
That's the big one, but the Implanon has also been linked to lower bone density.

00:07:03.629 --> 00:07:08.353
So in vulnerable patient groups we tend to recommend different ones.

00:07:08.353 --> 00:07:10.435
Oestrogen-containing ones would be ideal.

00:07:10.435 --> 00:07:16.899
And then the other group of patients are the ones that are on anti-epileptic medications, particularly Valproate.

00:07:16.899 --> 00:07:19.447
There's been a clear association with low bone mass.

00:07:19.889 --> 00:07:24.802
Right, you've already mentioned the diagnosis looking at a standard deviation of bone density, yep.

00:07:24.802 --> 00:07:29.307
That's obviously based on a DEXA score, which I always find very difficult to interpret.

00:07:29.307 --> 00:07:32.569
It's often two or three pages and there's a bunch of graphs and things.

00:07:32.569 --> 00:07:37.033
What's the easy way for the medical students and young GPs to try and interpret these results?

00:07:37.132 --> 00:07:37.432
Yeah.

00:07:37.432 --> 00:07:43.158
So I wanted to start by actually saying that Healthy Bones Australia has a really nice two-page PDF.

00:07:43.158 --> 00:07:48.785
It's got like a graphical diagram of how to go about interpreting a Dexan.

00:07:48.785 --> 00:07:52.023
I thought that was actually quite useful, even for myself, just as something to show people.

00:07:52.023 --> 00:07:57.482
But I would always start by first of all looking at the age of the patient.

00:07:57.482 --> 00:08:00.908
That plays a huge role in determining fracture risk.

00:08:01.771 --> 00:08:07.483
I then look at the T-scores to start with and assess whether or not they have osteopenia or osteoporosis.

00:08:07.483 --> 00:08:16.122
The Z-score is useful for determining A if the patient has maybe a secondary cause of osteoporosis.

00:08:16.122 --> 00:08:21.682
Largely speaking, a Z-score under minus two would prompt you to look for a secondary cause.

00:08:21.682 --> 00:08:29.317
And the reason for that is a Z-score is the number of deviations above or below bone density for an age-matched person.

00:08:29.317 --> 00:08:42.682
So you're really comparing with other people in that age group and if they've got much lower bone density than other people their age, then you think about whether there's celiac disease or primal hyperparathyroidism or something like that.

00:08:42.682 --> 00:08:53.707
And the other group that the Z-score is useful for are people that are under the age of 50, because the FRAX tools and all our risk calculations they're really aimed at people who are older.

00:08:53.707 --> 00:08:55.028
So the Z-score.

00:08:55.028 --> 00:08:57.384
You can't really use a T-score in that population either.

00:08:57.384 --> 00:08:58.900
Use the Z-score Then.

00:08:59.062 --> 00:09:03.571
The next thing I would look at, particularly for people who are on treatment.

00:09:03.571 --> 00:09:19.241
So when people have already been on treatment and you're following them up with a repeat bone density scan, I tend to look at the percentage change from the last scan and we would consider anything more than 4% in either direction to be a significant change.

00:09:19.241 --> 00:09:26.346
But most bone density centers will actually tell you whether or not they feel, according to their data, whether it's statistically significant.

00:09:26.346 --> 00:09:34.495
Significant, but the sort of zero to three percent change that's within what you could naturally find between repeat bone density scans.

00:09:34.495 --> 00:09:37.870
It might not be significant and that helps me to guide treatment.

00:09:37.870 --> 00:09:42.666
So I'll know if there's been deterioration despite standard treatment or whether there's been improvement.

00:09:43.307 --> 00:09:43.749
Excellent.

00:09:43.749 --> 00:09:50.722
You touched upon the FRAX score and I believe there's also a Garvin score and maybe a few other scores I'm not aware of, but these are two I've heard of.

00:09:50.722 --> 00:09:54.011
What is the utility of those and how do they help us?

00:09:54.860 --> 00:09:55.302
Absolutely.

00:09:55.302 --> 00:09:57.469
Those are the two that I know of as well.

00:09:57.469 --> 00:10:03.667
So the FRAX tool is more international and it takes into account a few other.

00:10:03.667 --> 00:10:05.419
It's got a few other questions as part of.

00:10:05.419 --> 00:10:17.880
It looks at glucocorticoid use, inflammatory conditions, alcohol intake, although I'm not sure to what degree those actually end up changing the FRAX tool, but they certainly are part of the questionnaire.

00:10:17.880 --> 00:10:28.385
The Garvin I like, particularly for people who have a lot of falls, because it takes into account falls per year and the frax doesn't.

00:10:28.385 --> 00:10:37.542
So if there's someone who has a lot of falls the frax may actually underestimate that fracture risk because of course if you're not falling you're much less likely to fracture.

00:10:37.542 --> 00:10:43.763
The other thing is the Garvin is, I think, australia based, so I like using that for our Australian population.

00:10:43.763 --> 00:10:47.852
I tend to go Garvin and then maybe might do the FRAX as a follow-up.

00:10:48.181 --> 00:10:50.048
So you do these routinely on your patients.

00:10:50.320 --> 00:10:51.482
So not routinely.

00:10:51.703 --> 00:10:53.388
That's a good point that you raised there.

00:10:53.589 --> 00:11:03.408
It's also worth pointing out that a lot of bone density scan centers will publish automatically their calculated FRAX score based on the bone density they've done on that day, and that's quite helpful.

00:11:04.028 --> 00:11:07.678
Generally score based on the bone density they've done on that day, and that's quite helpful.

00:11:07.678 --> 00:11:17.379
Generally, treatment is recommended for people who have a 10-year risk of at least 20% for any osteoporotic site and 3% for the hip, and if you exceed that then antiretroviral is recommended.

00:11:17.379 --> 00:11:28.605
So sometimes it's a clear-cut case someone who's broken their hip from a minimal trauma event, or a 75-year-old with a t-score of minus three those are clear indications for treatment.

00:11:28.605 --> 00:11:45.143
When it's a bit less clear for example a 50 year old with no fracture and a t-score of minus 2.5, or maybe a 65 year old with an osteopenia t-score of minus 2.3 those ones that are not clear cut but maybe have an elevated fracture risk I think those are where it's useful.

00:11:45.143 --> 00:11:54.296
And the other scenario where it might be useful are anxious patients who have a low fracture risk but say a 30 year old with a t-score of minus 2.5 and they're worried.

00:11:54.296 --> 00:11:59.681
I find that using the fracture calculator is really useful for reassuring them that their fracture risk is really low.

00:12:00.241 --> 00:12:05.774
And in these scenarios, that perhaps these younger patients particularly what would bring them to have a DEXA scan in the first place.

00:12:06.000 --> 00:12:13.102
I suppose the times that people may consider it is when there've been significant risk factors, things like.

00:12:13.102 --> 00:12:21.528
I've seen it done for prolonged periods of untreated hyperthyroidism or premature menopause or what we call primary ovarian insufficiency.

00:12:21.528 --> 00:12:29.769
In the younger population, and I do see it sometimes done in people who have anorexia nervosa, very low BMIs.

00:12:29.769 --> 00:12:35.206
I wouldn't say that it's appropriate to do it in those instances, but I can certainly understand why they've been done.

00:12:35.206 --> 00:12:40.169
The thing is that it may bring to light underlying low bone density.

00:12:40.169 --> 00:12:44.804
That doesn't end up having any clinical consequences because the risk of fracture is low.

00:12:44.804 --> 00:12:52.886
Low bone density is not the only determinant of fracture risk but on the other hand one could argue that it does prompt patients maybe to make some lifestyle changes.

00:12:52.886 --> 00:12:56.139
So get onto their vitamin D and their calcium intake and do more exercise.

00:12:56.139 --> 00:12:59.129
So I can see the pros and cons of both.

00:12:59.701 --> 00:13:03.410
So over the age of 50, screening is a tool that's recommended.

00:13:03.530 --> 00:13:27.106
Absolutely Between the ages of 50 and 65, and talking about the female population here, if they have an additional risk factor for osteoporosis, then screening with a DEXA scan is recommended, definitely Over the age of 65, it's recommended that all women just get a DEXA scan because they are long postmenopausal and the incidence of osteoporosis is very high in that population.

00:13:28.491 --> 00:13:31.621
Excellent, If we move on to actually further diagnostic tests.

00:13:31.621 --> 00:13:33.889
What's the role of bone turnover markers?

00:13:33.889 --> 00:13:38.671
I was actually reading about these and these are blood tests which I've never heard of until I prepared for this talk today.

00:13:39.320 --> 00:13:40.461
Yep, absolutely so.

00:13:40.461 --> 00:13:46.774
Look, the two main ones that I think most people will come across are the crosslaps, as we call them.

00:13:46.774 --> 00:14:03.611
They've got a much longer name, I think it's C-terminal telopeptide, and there's also the P1NP, and, to put it simply, crosslaps are an indicator of bone resorption and P1NP is a marker of bone formation.

00:14:03.611 --> 00:14:07.467
I don't ever really order a P1NP.

00:14:07.467 --> 00:14:18.328
It's used a lot in research, of course, and we'll talk a bit later about the bone building agents, and yes, those would be potentially raised, but practically we don't really monitor them.

00:14:18.328 --> 00:14:20.360
We just trust that the treatment's working.

00:14:20.400 --> 00:14:24.908
To be honest, crosslaps do have a major role in the management of osteoporosis.

00:14:24.908 --> 00:14:31.081
Crosslaps reduce quite quickly after starting anti-resorptive treatment.

00:14:31.081 --> 00:14:51.322
So within one to two weeks of starting a bisphosphonate, for example, cross-lapse will reduce by 50%, and for Prolia Denosumab, within a few days it will reduce quite significantly as well, and it's a really good indicator of reassuring ourselves that the anti-resorptive therapy is working.

00:14:51.322 --> 00:14:54.981
And I find that particularly useful in a few scenarios.

00:14:54.981 --> 00:14:58.312
The main one would be when you're treating someone with an oral bisphosphonate.

00:14:58.373 --> 00:15:03.235
Now, oral bisphosphonates are well known to be not the best absorbed drug.

00:15:03.235 --> 00:15:10.557
It's got a very low oral bioavailability and even in the best of scenarios, with a big glass of water, 30 minutes empty stomach.

00:15:10.557 --> 00:15:22.880
It may not be the best absorbed drug and it's useful to have cross-laps to do to reassure yourself that it's actually working and we aim for a cross-lapse under 400 to tell us that it's therapeutic.

00:15:22.880 --> 00:15:32.283
We'll talk a little bit later as well about the issues with prolia and stopping prolia, and we do use cross-laps as well to monitor the rebound reduction in bone density that occurs after the cessation of prolia and stopping prolia.

00:15:32.283 --> 00:15:38.013
And we do use cross-laps as well to monitor the rebound reduction in bone density that occurs after the cessation of prolia and how that guides us with managing those patients.

00:15:38.676 --> 00:15:41.465
Yeah, okay, so for the average person?

00:15:41.465 --> 00:15:44.916
Obviously most osteoporotic patients would be treated by their GP.

00:15:44.916 --> 00:15:51.860
We'll talk through the treatment methods in a minute, but there'll be occasional patients that may have greater osteoporosis or there may be some concern.

00:15:51.860 --> 00:15:55.350
What's the average patient that we referred to an endocrinologist for osteoporosis?

00:15:55.649 --> 00:16:12.674
Yeah, I see patients mainly who may be not satisfied with the standard treatments that are available bisphosphonates and or Prolia and they may want to explore things like hormone replacement therapy.

00:16:12.674 --> 00:16:14.033
They just want to get a second opinion.

00:16:14.033 --> 00:16:14.916
That's pretty common.

00:16:14.916 --> 00:16:29.024
We do get a lot of referrals for failure of treatment or patients who would benefit from zoledonic acid because there's quite a lack of accessibility for giving these infusions and I completely understand getting referrals for that.

00:16:29.024 --> 00:16:39.200
And with just going back to treatment failure, that's defined as patients who either have a deterioration in bone density or a minimal trauma fracture despite 12 months of adequate treatment.

00:16:39.200 --> 00:16:56.426
We do now have treatments that require specialist review for prescription on the PBS and we see those patients as well quite a lot, and I suppose any patient where they have osteoporosis and too many other things going on on CKD is the big one where we just need maybe more of a bigger picture.

00:16:56.908 --> 00:17:04.451
So balancing the kidney disorders with the osteoporosis and try to coordinate the calcium resorption and reabsorption from the kidneys?

00:17:04.471 --> 00:17:05.233
Yeah, absolutely so.

00:17:05.233 --> 00:17:06.457
We tend to see those quite a bit as well.

00:17:07.118 --> 00:17:10.840
Okay, excellent, we'll move on to the treatment of osteoporosis.

00:17:10.840 --> 00:17:11.545
I understood.

00:17:11.545 --> 00:17:19.873
You know, obviously, as a north big surgeon, about calcium and taking vitamin d and getting sunlight very important and that's about as much as I knew.

00:17:19.873 --> 00:17:24.555
I've heard about biphosphonates in the last few years, but when you look at it, there's a lot to it.

00:17:24.555 --> 00:17:28.291
There's so many different forms of treatment yeah we start off with the simple things first.

00:17:28.291 --> 00:17:33.983
Obviously, obviously preventative would be important reducing alcohol intake and doing exercise.

00:17:33.983 --> 00:17:35.896
Where do you go from there?

00:17:36.369 --> 00:17:39.279
Yeah, and look, I'm glad you brought up exercise.

00:17:39.279 --> 00:17:44.742
It's actually really important to also prescribe the type of exercise that should be done.

00:17:44.742 --> 00:17:56.992
A lot of the patients that you take a history from will say, yeah, I walk every day and the walking's good, but if they've already had a fall and a fracture, we really need to be looking at what more we can do for these patients and Healthy Bones.

00:17:56.992 --> 00:18:07.571
Australia actually has a really nice PDF again about exercise and they cover exercises for weight bearing and they also cover resistance training and balance training.

00:18:07.571 --> 00:18:23.983
So these are the three sort of categories of exercise, and balance training is really important for these patients, especially the ones who are falling over just ensuring that they can write themselves better if they trip and things like that and I think exercise physiology referral is absolutely reasonable as well.

00:18:25.067 --> 00:18:36.314
So with regards to finishing up on the lifestyle things, I guess I always make sure that patients are having adequate calcium, so the recommendation is at least 1200 milligrams for a postmenopausal woman per day, and that can look like different things.

00:18:36.314 --> 00:18:44.321
I usually have a little chart of calcium foods and there's also online calculators that people can use to make sure they're getting enough calcium and vitamin D.

00:18:44.321 --> 00:18:54.315
I think labs quote 60 is the normal range, but we know that you need sometimes need up to 80 to completely eliminate any sort of bone resorption.

00:18:54.315 --> 00:18:57.712
That's going on, yeah, and most of us need vitamin D supplementation.

00:18:57.712 --> 00:18:59.560
We're all indoors, so yeah.

00:18:59.560 --> 00:19:05.859
So that's the kind of we've covered the lifestyle things, the dietary things, and then moving on to pharmacological management.

00:19:05.859 --> 00:19:17.502
So I always split them up into two categories the bone, the antiresorptives, so the ones that prevent osteoclast action, and the bone building agents, or the anabolic agents.

00:19:17.502 --> 00:19:22.767
So, in terms of the antiresorptives, you mentioned the bisphosphonates.

00:19:22.767 --> 00:19:27.118
That's the oldest one we have, with the most data comes in oral form.

00:19:27.118 --> 00:19:29.673
Obviously, you've got weekly tablets, monthly tablets.

00:19:29.673 --> 00:19:38.234
Actonel, fosamax are the two main ones that we tend to prescribe, and then we've also got zoledronic acid, which is an intravenous infusion that we use yearly.

00:19:38.234 --> 00:19:41.122
Bisphosphonates, like I said, they're very old.

00:19:41.122 --> 00:19:42.252
They're very old medications.

00:19:42.252 --> 00:19:43.615
We've got lots of data on them.

00:19:43.615 --> 00:19:44.778
They work really well.

00:19:44.778 --> 00:19:52.558
The main side effect with the oral bisphosphonates are the gastrointestinal side effects and, like I mentioned before, the low bioavailability.

00:19:52.558 --> 00:20:10.381
So really emphasizing to patients that the mode of administration is really important, sticking to the advice provided by the pharmacy, and I tend to avoid it in patients who have had upper gastrointestinal surgeries or esophageal strictures, anything where that drug might get stuck.

00:20:10.381 --> 00:20:12.871
I don't, yeah, I don't recommend it.

00:20:13.571 --> 00:20:15.215
Intravenous bisphosphonates.

00:20:15.215 --> 00:20:17.180
So the main one we use obviously is zoledronic acid.

00:20:17.180 --> 00:20:23.932
I like that it bypasses the gastrointestinal tracts, are really good for those that do get reflux and symptoms like that.

00:20:23.932 --> 00:20:27.760
The main side effect is flu-like symptoms.

00:20:27.760 --> 00:20:30.948
In some patients it can be pretty severe as well.

00:20:30.948 --> 00:20:33.954
They can get this really run down malaise.

00:20:33.954 --> 00:20:38.574
They can get the headaches and body aches and joint pains and things and it can be quite off-putting.

00:20:38.574 --> 00:20:47.442
If they've not expected it, I generally tell patients to take paracetamol three days prior leading up to the infusion and on the day of as well.

00:20:47.442 --> 00:20:53.019
They can take it after as well if they want, and that's actually been shown in the literature to be useful.

00:20:53.019 --> 00:20:58.554
I have also seen in clinical practice patients who have really severe reactions.

00:20:58.554 --> 00:21:04.195
The next one they might take a small one-off dose of a corticosteroids, so 25 milligrams of prednisolone or something like that.

00:21:04.195 --> 00:21:07.092
But yeah, those would be the main side effects.

00:21:07.092 --> 00:21:09.416
So those are the bisphosphonates.

00:21:09.537 --> 00:21:14.175
The other anti-resorptive that we see a lot of is Prolia, the denosumab.

00:21:14.175 --> 00:21:22.256
So denosumab is a monoclonal antibody against rank ligand and it's a very potent inhibitor of osteoclastic action.

00:21:22.256 --> 00:21:36.262
It works extremely well, but the main downside is that it only works while it's in the system, so it has to be given every six months pretty strictly, and it also can't be stopped.

00:21:36.262 --> 00:21:45.234
So it's meant to be in an indefinite treatment and cessation is not recommended unless it's covered by something else, and even then there are nuances issues with that.

00:21:45.977 --> 00:21:54.142
And if it is seized without anything to replace it, you can get a pretty profound bone density rebound, bone density loss.

00:21:54.471 --> 00:22:02.761
There's also an increased risk of multiple vertebral fractures in the spine and actually by two years post-cessation it's almost like you've never been on any prolia at all.

00:22:02.761 --> 00:22:08.643
So you actually go back to being on essentially similar to placebo, yeah, yeah.

00:22:08.643 --> 00:22:20.413
So quite a profound and significant issue there with the denosumab and I see it prescribed a lot in the younger population it's such a convenient drug you inject it and forget it.

00:22:20.413 --> 00:22:43.743
But I am now actually seeing more and more gps, I think, being made aware of the issues with denosumab, and we do get a lot more referrals now for people who have been started on denosumab either by a different GP or a specialist or hospital and they're saying can you please help us get this patient off denosumab because they're way too young to be on it Anyone over the age of 80 or someone who's got a lower life expectancy.

00:22:43.743 --> 00:22:46.393
I think very reasonable to be on denosumab.

00:22:46.393 --> 00:22:51.383
We've got data going up to 10 years for the safety and efficacy, but we don't have much beyond that.

00:22:51.829 --> 00:23:00.777
So in these osteoclastic reduction, osteoclastic activity they don't obviously increase the actual bone density, they just reduce the actual loss.

00:23:00.777 --> 00:23:01.759
Is that correct?

00:23:01.890 --> 00:23:08.769
So it yes, it doesn't affect the osteoblast, so it doesn't actually cause any bone formation.

00:23:08.769 --> 00:23:15.835
But by reducing osteoclastic activity alone that can, I guess, improve you could say the balance between the two.

00:23:15.835 --> 00:23:18.582
And we do see increases in in bone density.

00:23:18.582 --> 00:23:21.298
We do see that particularly with prolia in the spine.

00:23:21.298 --> 00:23:23.885
It's got quite a marked improvement.

00:23:23.925 --> 00:23:28.601
But we see that with bisphosphonates as well yeah, so that leads to a change in their percentage.

00:23:28.601 --> 00:23:30.923
They may move from a lower t value or z value, depending on their age group to a change in their percentage.

00:23:30.923 --> 00:23:39.219
They may move from a lower T value or Z value, depending on their age group, to a higher T value in that situation I would be satisfied if they just didn't lose bone.

00:23:39.410 --> 00:23:44.561
But very often we do see and expect them to gain some bone as well, right, yep.

00:23:44.982 --> 00:23:50.298
Okay, Moving away from those osteoclastic drugs are there any other we need to look at, or is that the main ones?

00:23:56.470 --> 00:23:57.712
Well, there are the ones that we use less commonly in women.

00:23:57.712 --> 00:24:06.921
So we've got raloxifene, which is a selective estrogen receptor modulator and it's an estrogen agonist on bone, but it's an antagonist on breast and uterine tissue.

00:24:06.921 --> 00:24:11.878
It's an oral medication and it's indicated for postmenopausal women with osteoporosis.

00:24:11.878 --> 00:24:23.060
We tend not to use it in people who've had venous thromboembolisms or people at a higher clotting risk, because it can potentially increase the risk of VTE or venous thromboembolism.

00:24:24.269 --> 00:24:27.102
And the last one, just to mention in passing as well, is tibalone.

00:24:27.102 --> 00:24:32.901
So tibalone is a synthetic steroid that has estrogenic and progestogenic effects.

00:24:32.901 --> 00:24:40.153
It's also an oral medication and it's also indicated for postmenopausal osteoporosis and we tend to choose this one.

00:24:40.153 --> 00:24:49.799
For women who also have vasomotor symptoms of menopause they get a lot of hot flushes but for whatever reason they can't have HRT then tibalone might be something that we can consider.

00:24:49.799 --> 00:24:52.271
And of course, we should mention HRT.

00:24:52.271 --> 00:24:56.163
Estrogen is a very good suppressor of bone resorption.

00:24:56.163 --> 00:25:13.032
We don't recommend using it as first line treatment in someone who needs anti-resorptive treatment, but if they have troubling vasomotor symptoms of menopause and they've got an increased risk of fracture although not a very high risk of fracture then HRT is a great option for those women.

00:25:13.453 --> 00:25:13.934
Excellent.

00:25:13.934 --> 00:25:17.231
So there's numerous different options depending on the scenario.

00:25:17.231 --> 00:25:20.961
Obviously, it's not one size fits all.

00:25:20.961 --> 00:25:22.926
What about the osteoblastic drugs?

00:25:22.926 --> 00:25:24.611
Are these newer agents?

00:25:24.611 --> 00:25:26.355
Because I've not really heard too much about these.

00:25:26.556 --> 00:25:30.515
Yeah, they definitely tend to be ones that endocrinologists prescribe.

00:25:30.515 --> 00:25:33.923
The two that we have on the market are teriparatide.

00:25:33.923 --> 00:25:37.240
So teriparatide is a synthetic PTH analog.

00:25:37.240 --> 00:25:45.923
It's been around for ages, although under continuous parathyroid hormone stimulation, bones tend to become osteoporotic.

00:25:45.923 --> 00:25:54.519
What they've found is that when you expose bone to intermittent PTH stimulation, it actually helps build bones, actually got an osteoblastic activity.

00:25:54.519 --> 00:25:57.038
So that's how teriparatide works.

00:25:57.569 --> 00:26:07.116
It's a daily subcutaneous injection which, as you can imagine, brings its own challenges with getting patients to agree to have it, but it's pretty safe.

00:26:07.116 --> 00:26:09.337
We've got lots of data, long-term data, on it.

00:26:09.337 --> 00:26:17.741
It's safe in a wide range of kidney functions and it's safe in people that have a higher cardiovascular risk as well.

00:26:17.741 --> 00:26:24.221
So it's a really good option there as well, and it's given for 18 to 24 months.

00:26:24.221 --> 00:26:30.165
So it's PBS subsidized for 18 months, but it's been proven to be beneficial beyond that, up to 24 months.

00:26:30.688 --> 00:26:33.972
After 24 months there is a black box warning for development of osteosarcoma.

00:26:33.972 --> 00:26:35.473
We always stop at 24.

00:26:35.473 --> 00:27:16.644
So the main limitation with prescribing on the PBS is the fact that you need very severe osteoporosis, so a T-score of minus 3.0 or less, and you need to have had at least two minimal trauma fractures, and one has to be on standard treatment and lots of barriers there, but we do see patients who qualify and I've prescribed it certainly a few times Yep, and but it's usually well tolerated, usually very well tolerated they self-administer the injections themselves right yep, so it's definitely been shown to significantly increase bone density, and both anabolic agents of teriparatide and romisazumab, which we'll talk about next, both of these need to be consolidated.

00:27:16.904 --> 00:27:28.067
When we say that, we mean you need to lock it in with either Prolia or a bisphosphonate in order to secure that bone building and prevent sort of loss of what was gained.

00:27:28.855 --> 00:27:32.787
So it's used at the same time, or once the first one stops, you start the second one.

00:27:33.115 --> 00:27:41.601
Classically we stop the anti-resorptive, put on the anabolic agent, finish the course and then consolidate.

00:27:41.601 --> 00:27:47.455
But there have been some people that have been looking at using teriparatide and denosumab together and that's been.

00:27:47.455 --> 00:27:49.463
There's been some positive results there.

00:27:49.463 --> 00:27:56.143
Obviously that wouldn't work on the PBS because you can't be on an anti-resorptive when you're on an anabolic.

00:27:56.143 --> 00:28:03.076
But if one, if a person, if an individual was happy to self-fund one or the other, then technically it could be done.

00:28:03.577 --> 00:28:17.458
But apart from teriparatide with denosumab together, I'm not familiar with any other concurrent treatments okay, so classically one than the other okay, and then one last drug to go through is that's it so romisosumab.

00:28:17.478 --> 00:28:18.240
That's the newest one that we have.

00:28:18.240 --> 00:28:19.343
It's a fast drug to go through, isn't it?

00:28:19.343 --> 00:28:19.663
That's it.

00:28:19.663 --> 00:28:21.429
So romisozumab that's the newest one that we have.

00:28:21.429 --> 00:28:24.785
It's a monthly injection.

00:28:24.785 --> 00:28:35.945
It's actually two injections for whatever reason, but you inject them at the same time in two different sites and it's a monthly injection for a total of 12 months.

00:28:35.945 --> 00:28:41.308
And they've never done head-to-head trials between teriparatide and romisozumab.

00:28:41.308 --> 00:28:48.058
But just looking at numbers alone, it's suggesting that the romisozumab is probably more efficacious in increasing bone density.

00:28:48.921 --> 00:28:57.480
The main issue with romisozumab is that there is a small but theoretical risk of increased cardiovascular events.

00:28:57.480 --> 00:29:00.826
Now, it wasn't found to be statistically significant.

00:29:00.826 --> 00:29:08.256
I think the numbers were something like 2.5% in the romisozumab population versus 1.9% in the alendronate.

00:29:08.256 --> 00:29:29.313
So it wasn't statistically significant, but it was enough to make people worried and certainly enough for the company to put out a warning that they wouldn't recommend prescribing this drug in anyone with a heart, a cardioinfarction or a cerebrovascular event in the last 12 months, and certainly in the older, more frail, comorbid population.

00:29:29.313 --> 00:29:34.545
I am very hesitant and would probably opt for the teriparatide instead because of that warning.

00:29:35.446 --> 00:29:39.001
But apart from that, it is easy to administer.

00:29:39.001 --> 00:29:43.259
You just get them to book it in with their nurse and they usually tolerate it really well.

00:29:43.259 --> 00:29:50.163
I usually just check their calcium at the six month mark just to make sure that's not risen significantly.

00:29:50.163 --> 00:29:54.318
But it's a listed thing to look at but never really seen it be an issue.

00:29:54.318 --> 00:29:58.855
And then after the 12 months again they need to have consolidation.

00:29:58.855 --> 00:30:17.234
The slight difference with romisozumab is that there's really good evidence that upfront, first-line romisozumab so they've never had any anti-resorptive is actually the most beneficial and PBS in the last little while have started subsidizing romisozumab as first-line treatment.

00:30:17.234 --> 00:30:26.190
But again there are some strict criteria, again relating to very low T-scores and having specific symptomatic fractures within the last 24 months.

00:30:26.190 --> 00:30:34.597
But certainly if a patient fits that brief, absolutely would recommend being on romisozumab if they can Brilliant.

00:30:35.460 --> 00:30:48.086
All these drugs are trying to reduce the amount of bone resorption or increase the bone formation, and they're the numbers we're looking at, that we actually have figures, and how will they actually prevent fractures or reduce the complications of fractures at all?

00:30:48.548 --> 00:30:49.872
yep, yep, absolutely.

00:30:49.872 --> 00:30:50.734
You're absolutely right.

00:30:50.734 --> 00:30:54.384
So, at the end of the day, why do we care about improving bone density?

00:30:54.384 --> 00:30:58.560
It's not just to have a number go up, it's actually to reduce fracture risk.

00:30:58.560 --> 00:31:03.941
So I know for a fact that bisphosphonates have fracture risk in individuals.

00:31:03.941 --> 00:31:05.084
I always tell them.

00:31:05.084 --> 00:31:08.363
It doesn't make them bulletproof, though, so they still need to be really careful.

00:31:08.363 --> 00:31:11.978
If you have fractured before, you can fracture again, even with the best treatment.

00:31:11.978 --> 00:31:14.325
But yes, bisphosphonates have fracture risk.

00:31:14.325 --> 00:31:22.140
I don't know off the top of my head the numbers for the other agents, but they've all been shown to reduce fractures and not just improve bone density.

00:31:22.642 --> 00:31:23.044
Excellent.

00:31:23.044 --> 00:31:33.392
You've mentioned some of the side effects of the drugs as we've gone, obviously the one that a lot of people might've heard about, the bisphosphonates, the risks of osteonecrosis of the jaw or unusual femoral fractures as well.

00:31:33.392 --> 00:31:34.615
What are your thoughts on those?

00:31:35.136 --> 00:31:38.942
Yeah, yep, so we'll start with the osteonecrosis of the jaw.

00:31:38.942 --> 00:31:42.710
So everyone's really worried about it, and that's reasonable.

00:31:42.710 --> 00:31:47.027
It can be catastrophic and treatment can be prolonged and difficult.

00:31:47.027 --> 00:31:52.946
Osteonecrosis of the jaw is actually really uncommon in the osteoporosis population.

00:31:52.946 --> 00:32:01.943
It's better described in the oncology population, where they get much bigger doses and more frequent doses of these medications.

00:32:01.943 --> 00:32:08.968
But the incidence in the osteoporotic population is something between 0.001 to 0.15%.

00:32:08.968 --> 00:32:18.142
So it is a pretty unusual complication to have and if you know how to prevent it and which populations are most at risk, then it's very avoidable.

00:32:18.221 --> 00:32:27.207
The biggest risk factors are, of course, being on an anti-resorptive, but apart from that, having poor dentition or active suppurative dental disease.

00:32:27.207 --> 00:32:33.497
So periodontal disease and things like that, those would be the main risk factors, and also having a recent dental extraction.

00:32:33.497 --> 00:32:35.223
That's one of the biggest risk factors as well.

00:32:35.223 --> 00:32:38.094
So it's always about prevention.

00:32:38.094 --> 00:32:42.066
Whenever you're about to start someone on treatment, always have a quick look in their mouth.

00:32:42.066 --> 00:32:49.346
If they're happy to get a dental review, that would be the best, but as long as they've not had any active dental issues, it's not the end of the world.

00:32:49.346 --> 00:32:59.161
I now get most patients just to do a dental review, because you never know when there's something that's asymptomatic that gets picked up, they can have that fixed before they then go down the route.

00:32:59.721 --> 00:33:03.048
Like I said, if they need something done emergently, it can be done.

00:33:03.048 --> 00:33:10.994
Now we don't have any good ways of knowing when's the best time.

00:33:10.994 --> 00:33:15.787
I guess it makes sense that you would aim to do it just before the next dose for Prolia, because you can't stop it.

00:33:15.787 --> 00:33:23.038
You would do it maybe month four, so that they've got a whole month to recover before their next dose With bisphosphonates.

00:33:23.038 --> 00:33:26.686
If they're on an oral bisphosphonate, definitely stop it.

00:33:26.686 --> 00:33:29.000
It's no rebound bone loss, so that's fine.

00:33:29.000 --> 00:33:40.221
And with the zoledronic acid I don't think there's any hard and fast rule, but I would maybe aim to do it maybe six months, at least three to six months after their last dose, before they have any dental work done.

00:33:40.301 --> 00:33:44.249
But if they can have it, all done before starting, then it eliminates a lot of issues after.

00:33:44.575 --> 00:33:48.945
So these risks are for all the anti-resorptive medications is it Essentially.

00:33:48.987 --> 00:33:52.423
Yes, so bisphosphonates and denosumab equally Okay.

00:33:52.785 --> 00:33:55.397
Right, okay, what about the femoral shaft fractures?

00:33:55.397 --> 00:33:57.521
The proximal subtrochanteric type fractures that we will see occasionally?

00:33:57.521 --> 00:34:00.207
Yes, the proximal subtrochondriac type fractures that we will see occasionally?

00:34:00.247 --> 00:34:06.756
Yes, absolutely so.

00:34:06.756 --> 00:34:09.559
I'll probably start by just saying a little bit about atypical femoral fractures or AFFs.

00:34:09.559 --> 00:34:15.369
So AFFs are generally no trauma or minimal trauma fractures that occur in generally the femoral shaft.

00:34:15.369 --> 00:34:22.672
They have quite specific radiological features that help us to differentiate it from your typical femoral fractures, have quite specific radiological features that help us to differentiate it from your typical femoral fractures.

00:34:22.672 --> 00:34:26.237
They tend to start laterally in the cortex and then move inwards, either transversely or obliquely.

00:34:26.237 --> 00:34:31.119
And you can also get some incomplete ones that just show as like a little bit of beaking at the side.

00:34:31.119 --> 00:34:36.516
That can be quite subtle, but they are associated with prolonged bisphosphonate use.

00:34:36.516 --> 00:34:38.583
Now the risk of AFFs go up even within the first year of bisphosphonate use.

00:34:38.583 --> 00:34:45.101
Now, the risk of AFFs go up even within the first year of bisphosphonate use, but goes up significantly after five years.

00:34:45.101 --> 00:34:55.286
And in saying that, once you stop bisphosphonates, the risk of AFF also drops quite significantly after cessation.

00:34:55.286 --> 00:34:56.449
So that's good to know.

00:34:56.449 --> 00:35:03.824
All the antiresorptives are associated with AFFs, but it appears that bisphosphonates more so than denosumab.

00:35:03.824 --> 00:35:08.570
The other thing to note is that AFFs in general are rare.

00:35:08.570 --> 00:35:11.523
They're very rare and they're difficult to study because they're so rare.

00:35:11.523 --> 00:35:18.507
And the other thing to note is that patients who have osteoporosis are also more likely to have AFFs.

00:35:18.507 --> 00:35:23.382
Anyway, you can have AFFs without being on bisphosphonates and we do see that happen sometimes.

00:35:23.943 --> 00:35:33.579
I think this brings us to our next kind of topic about drug holidays, because that's something that's discussed a lot and GPs do ask me a lot of questions about drug holidays.

00:35:33.579 --> 00:35:42.784
So a drug holiday basically means, after a period of time of being on a bisphosphonate, taking one to two years off the bisphosphonate to reduce the risk of AFFs.

00:35:42.784 --> 00:35:47.579
Now drug holidays are recommended in people with a low to intermediate risk of fracture.

00:35:47.579 --> 00:35:56.577
If they've, say, had a T-score of minus 2.5 and then you treated them with a bisphosphonate and now they're just osteopenic, they've not had any fractures you could definitely consider a drug holiday.

00:35:56.577 --> 00:36:07.231
But official guidelines actually say not to consider it if they're still at a high risk of fracture, so they've had a recent fracture or t-scores are still below minus 2.5.

00:36:07.231 --> 00:36:22.786
They actually recommend that you keep going because even at the 10-year mark of being on a bisphosphonate for most of the population, even then the risk of fracture from a from minimal trauma typical fracture would be higher than the risk of an AFF.

00:36:22.786 --> 00:36:25.664
So that's something to be aware of.

00:36:26.175 --> 00:36:32.724
Yeah, I think it's quite commonly known that a person who breaks their hip has got a high risk of mortality in the first year after that.

00:36:32.974 --> 00:36:34.501
Absolutely, absolutely.

00:36:34.501 --> 00:36:39.054
So we'd rather prevent that than an incomplete AFF, say.

00:36:39.054 --> 00:36:43.619
And the other thing to mention is that we can be on the lookout for these.

00:36:43.619 --> 00:36:59.884
So if you've got a patient who's on long-term bisphosphonates, just always asking them about groin pain, and if they do mention any groin pain, just doing a bilateral x-ray, you can then refer them on to our colleagues, like yourself, and see whether they'd be suitable for fixation.

00:37:01.476 --> 00:37:10.298
Lynn, once you've got these patients on the medications treating them, how should these patients be monitored, and what are the red flags for treatment failure in these scenarios too, that you need to take into account?

00:37:11.181 --> 00:37:11.862
Yep, absolutely.

00:37:11.862 --> 00:37:12.083
So.

00:37:12.083 --> 00:37:14.039
We touched on brain turnover markers.

00:37:14.039 --> 00:37:25.844
So cross-laps I would recommend doing cross-laps at least three months into treatment just to, particularly with the oral bisphosphonates, just to make sure that they're doing their job For the duration of treatment.

00:37:25.844 --> 00:37:40.978
I also do regular, at least six-monthly, biochemistry to check their renal function, because there are limitations on treatment with bisphosphonates, so you're not meant to use them, the bisphosphonates, particularly with an EGFR under 30.

00:37:41.518 --> 00:37:46.121
I still use oral bisphosphonates in that CKD population, but cautiously.

00:37:46.121 --> 00:37:50.525
And of course the risk of side effects with denosumab goes up quite a bit.

00:37:50.525 --> 00:37:57.371
If you've got CKD you can develop hypocalcemia which can send patients to ICU and be very symptomatic.

00:37:57.371 --> 00:38:00.500
So that's something to look out for as well, always monitoring the renal function.

00:38:00.500 --> 00:38:13.563
I do also monitor their vitamin D, particularly before a denosumab dose or a zoledronic acid dose, and give them high dose vitamin D to boost them up quickly, to make sure that we also reduce that risk of hypocalcemia after treatment.

00:38:13.563 --> 00:38:26.019
And I would also just check their calcium just to make sure they're not hypocalcemic for whatever reason to start with, because we would definitely need to manage that before they get something that could potentially make them even more hypocalcemic.

00:38:27.039 --> 00:38:27.880
And the DEXA scans.

00:38:27.880 --> 00:38:31.402
I think you said every couple of years after you've started treatment.

00:38:31.501 --> 00:38:37.905
Yes, so if you've just started treatment, you can get a MBS-rebatable DEXA scan within one year.

00:38:37.905 --> 00:38:41.827
Otherwise, the other scans are generally every two years.

00:38:41.827 --> 00:38:44.608
So I'd be happy to do one after one year of treatment.

00:38:44.608 --> 00:38:47.809
Usually, patients are quite keen to see how their bone density is doing as well.

00:38:47.809 --> 00:38:48.809
So that would be reasonable.

00:38:49.550 --> 00:38:50.391
Excellent, all right.

00:38:50.391 --> 00:38:54.012
What's the difference between treating a female patient and a male patient?

00:38:54.012 --> 00:38:55.333
Is there any difference you look into?

00:38:55.333 --> 00:38:59.943
Obviously, some of the medications we talked about are indicated in postmenopausal ladies.

00:38:59.943 --> 00:39:01.827
That may not be the scenario for men.

00:39:01.827 --> 00:39:03.922
Does that affect how you treat them?

00:39:04.735 --> 00:39:07.764
So ultimately, the same principles still apply for treatment.

00:39:07.764 --> 00:39:14.835
It's all about whether they've had a fracture, how low their bone density is and what their calculated fracture risk is using those tools that we discussed.

00:39:14.835 --> 00:39:22.628
I think the main differences are actually with regards to maybe the more nuanced conditions around osteoporosis.

00:39:22.628 --> 00:39:29.898
For example, if we look at hypogonadism, a common secondary cause of osteoporosis in men is testosterone deficiency.

00:39:29.898 --> 00:40:04.019
Now, men may benefit from testosterone replacement for other reasons energy, libido, things like that but it's actually not been shown that testosterone replacement improves fracture risk, and in fact, it's been shown that it goes the other way around, and we don't know if that's because men just get so much energy they're jumping around falling over, but it does increase bone density, but that has not translated to fracture risk, whereas for women who have had estrogen deficiency, we know that it prevents fractures and it improves bone density.

00:40:04.019 --> 00:40:06.485
So that's probably one of the main things to be aware of.

00:40:06.715 --> 00:40:08.260
Okay, that's an interesting fact to know.

00:40:08.260 --> 00:40:11.940
So where do you think things are heading for the future in the treatment of osteoporosis?

00:40:11.940 --> 00:40:14.487
I know we focus on calcium as a major issue.

00:40:14.487 --> 00:40:16.157
Where do you think things will be in the future?

00:40:17.099 --> 00:40:24.422
Yeah, there's lots of things on the horizon, as with, I'm sure, every field of medicine, so we could talk a little bit about trabecular bone score.

00:40:24.422 --> 00:40:42.329
So trabecular bone score is a measurement of bone microarchitecture and it's taken as a measurement of the lumbar spine, which is obviously it is mainly trabecular bone, and it just adds more information to help the clinician assess fracture risk.

00:40:42.329 --> 00:41:02.385
Most centers don't offer a trabecular bone score, but there are some that do and that can certainly be used to help with decision-making, particularly in intermediate risk patients or patients who are just on the threshold of indications for treatment, and I think as we learn more about how to use it, it will become a more useful tool.

00:41:02.385 --> 00:41:06.590
And then I believe there are also on the horizon.

00:41:06.590 --> 00:41:20.603
There's also the development of other anabolic treatments, potentially dual action agents as well, to address both osteoclastic activity and osteoplastic activity, and also looking at different sorts of bone markers that can help us.

00:41:28.434 --> 00:41:28.615
Excellent.

00:41:28.635 --> 00:41:30.885
Hopefully one day these people, will be bulletproof and we'll be a lot less work for ourselves in orthopaedics.

00:41:30.885 --> 00:41:31.327
Absolutely absolutely.

00:41:31.347 --> 00:41:32.231
Thank you very much, Lynn.

00:41:32.231 --> 00:41:33.778
It's been fantastic having you here.

00:41:33.938 --> 00:41:34.722
Thank you for having me.

00:41:34.864 --> 00:41:37.376
And it's been really great hearing about these different agents.

00:41:37.376 --> 00:41:41.184
The main thought that came through my head, and a lot of the way through, was the bifosfinates.

00:41:41.184 --> 00:41:42.688
I was remembering when they were just being released.

00:41:42.688 --> 00:41:45.820
An old agent shows how old I am.

00:41:45.820 --> 00:41:48.266
It's all good fun.

00:41:48.315 --> 00:41:49.483
They've always been in my textbooks.

00:41:49.614 --> 00:41:50.639
Thank you very much for coming on.

00:41:50.639 --> 00:41:51.121
Aussie Med Ed.

00:41:51.121 --> 00:41:53.338
It's been great to have you, it's been a pleasure, thank you.

00:41:53.338 --> 00:41:54.300
Thank you very much.

00:41:54.300 --> 00:41:55.965
Thank you, dr Lynn Lee.

00:41:55.965 --> 00:42:02.070
I'd like to remind you that all the information presented today is just one opinion and there are numerous ways of treating all medical conditions.

00:42:02.070 --> 00:42:06.492
It's just general advice and may vary depending upon the region in which you are practicing or being treated.

00:42:06.492 --> 00:42:14.525
The information may not be appropriate for your situation or health condition and you should always seek the advice from your health professionals in the area in which you live.

00:42:14.525 --> 00:42:23.168
Also, if you have any concerns about the information raised today, please speak to your GP or seek assistance from health organisations such as Lifeline in Australia.

00:42:23.168 --> 00:42:28.242
Thanks again for listening to the podcast and please subscribe to the podcast for the next episode.

00:42:28.242 --> 00:42:30.405
Until then, please stay safe.

Linn Lee Profile Photo

Linn Lee

Endocrinologist, Chemical Pathology Registrar

Dr Linn Lee graduated from the University of Adelaide in 2016 and completed her specialist training in Endocrinology at the Lyell McEwin Hospital and Flinders Medical Centre. In 2024, she was admitted as a Fellow of the Royal Australasian College of Physicians.

Linn now practices as a private endocrinologist at South Australian Medical Specialists, Hove. She provides comprehensive care in all areas of general endocrinology, with particular interests in bone health, reproductive endocrinology, and diabetes management. Linn is also currently completing dual training in Chemical Pathology, further expanding her expertise in the biochemical and diagnostic aspects of endocrine health.

When not at work, Linn loves reading, painting, going for walks, and spending quality time with her friends and loved ones, while enjoying delicious food and good coffee.